Background: The endogenous factors contributing to long-term changes in body weight are not known but the regulation of energy metabolism by different beta-adrenoceptors (b 1 -AR, b 2 -AR, b 3 -AR) or alpha-adrenoceptors (a 2 -AR) may play a role. Methods: In a prospective study, we investigated b-AR and a 2 -AR subtype function in subcutaneous fat cells of 85 healthy, nonobese women by using a standardized bioassay of lipolysis. Of these 73 were re-investigated on an average 10 years later to compare baseline function of b 1 -AR, b 2 -AR, b 3 -AR and a 2 -AR with longitudinal weight changes. Results: Weight change over time was normally distributed ranging fromÀ4 kg/m 2 to þ 6 kg/m 2 in body mass index. Long-term changes in body weight correlated inversely with b 3 -AR function at base line (r ¼ 0.5, P ¼ 0.001). Those with low b 3À AR function gained weight, whereas the opposite was observed with those who had a high b 3 -AR function. Nineteen percent of weight changes could be explained by b 3 -AR status. No relationship with weight changes was observed as regards the function of a 2 -AR, b 1 -AR or b 2 -AR function. Conclusions: b 3 -ARs are important for long-term changes in body weight putting energy metabolism in adipose tissue in frontline among endogenous factors that regulate body weight in adulthood.
Introduction
Although the prevalence of overweight and obesity is rising rapidly across the world, 1 not all adults increase their weight over time. For example, in a nationally representative cohort of US adults, only about half of the population increased their body weight over an 8-year observation period. 2 Physical inactivity and excess energy intake contribute to the global rise in excess body weight. 3 However, intrinsic factors must also play a role as shown by long-term overfeeding experiments with identical twins. 4 These endogenous factors are unknown so far. Sympathetic regulation of resting energy metabolism, which accounts for over 50% of adult energy expenditure, could play a role as discussed. 5 Resting metabolic rate is predictive of future weight gain in some populations as reviewed. 6 The metabolic rate is stimulated by beta-adrenergic receptors (b-AR). It is well-established that treatment with b-blockers causes weight gain, which presumably is because of a decrease in metabolic rate. 7 There is indirect evidence that all three known b-AR subtypes (b 1 , b 2 and b 3 ) regulate body weight among adults because polymorphism in the genes that encode either of these receptors is associated with weight gain in longitudinal studies. [8] [9] [10] [11] [12] [13] [14] To assess whether the b-AR function predicts future changes in body weight we conducted a long-term prospective study on the function of b 1 -AR, b 2 -AR and b 3 -AR in isolated subcutaneous fat cells from healthy non-obese women. The fat cells are central for energy homeostasis because white adipose tissue mobilizes energy in the form of fatty acids through lipolysis and brown adipose tissue stimulates thermogenesis; these effects are mediated through the three b-AR subtypes as discussed. 15 In addition, human fat cells have also an antilipolytic a 2 -adrenoceptor (a 2 -AR) and there is a relationship between the activity of these receptors and dietaryinduced weight loss. 16 Therefore, a 2 -ARs were studied as well.
Subjects and methods

Subjects
During 1990-1999 we recruited 85 healthy, non-obese women (body mass index, BMI, o30 kg/m 2 ) who were free of chronic medication for a standardized bioassay of b-AR and a 2 -AR function based on adipocyte lipolysis. 17 All were of Scandinavian origin and lived in the Stockholm area. They came to the laboratory in the morning after an overnight fast. After determination of height and weight a venous blood sample was obtained. DNA was isolated from blood and stored at À20 1C for future genetic analysis. A surgical incision was made under local anaesthesia 18 in the abdominal region and about 1 g of subcutaneous adipose tissue was removed and immediately subjected to lipolysis investigation. During November-December 2004, all women were contacted by letter for information of actual body weight (by self report) and questions regarding events, which had occurred during the observation period and might have influenced body weight. These events were long-term disease or medical treatment, occurrence of pregnancy or menopause, slimming attempts and a change in lifestyle (diet, use of nicotine or alcohol and physical activity). These events were categorized as a dichotomous variable (one or several events, no event). Seventy-three women (86%) answered the questionnaire (the study group) and were asked to come to the laboratory in the morning after an overnight fast for a standardised measure of height and body weight. Thirtyeight women (52%) could come and were investigated between April and May 2005 or height and weight. The study was approved by the Hospital's committee on ethics. It was explained in detail to each participant and her informed consent was obtained.
Fat cell experiments
The methods to study adipocyte lipolysis and cellularity have been described in detail. 17 In brief, fat cells were isolated by collagenase treatment of adipose tissue and mean fat cell size and weight were determined. Diluted adipocyte suspensions (2% vol/vol) were incubated for 2 h at 37 1C in a Krebs-Henseleit-phosphate buffer containing bovine albumin (20 g l
À1
), glucose (1 g l
) and ascorbic acid (0.1 g l
). In clonidine experiments, (see below) the medium was also supplemented with adenosine deaminase (1 mU l À1 ). At the end of incubation, glycerol release into the medium (lipolysis index) was determined and related to the number of incubated fat cells. The cells were incubated in the absence (basal) or presence of either of the following agents (10 -10 -10 -4 mol l
), which were added to the incubation medium at start of the experiments: dobutamine (selective b 1 -agonist), terbutaline (selective b 2 -agonist), CGP 12177 (selective b 3 -AR agonist) or clonidine (selective a 2 -AR agonist). Owing to the lack of tissue it was not always possible to use all agonists in each subject. In addition, the method to study b 3 -AR with CGP 12177 was not available in the first 20 of the women. We and others have shown, first, the b-AR subtype-specific effects on lipolysis in human subcutaneous adipocytes of the three selective b-AR agonists and, second, the lack of b 1 -AR lipolytic effects of CGP 12177. [19] [20] [21] [22] As human subcutaneous fat cells have functional spare b-AR and a 2 -AR, 23 it is possible to evaluate adrenoceptor function by classical pharmacological methods. 24 The individual concentration-response curves were linearized by log-logit transformation and analyzed for pD2 (negative logarithm of half-maximum effective concentration). Responsiveness (glycerol release at maximum effective concentration) was determined from the original curves, which always reached a plateau. Responsiveness was expressed as glycerol release at maximum effective concentration divided by basal glycerol release. pD2 reflects receptor-related events (binding and coupling to effectors) and responsiveness reflects more distal and post-receptor events in a signal transduction system that is characterized by functional spare receptors. 24 In the presently used in vitro system to assess lipolysis the rate of glycerol release and effect of b-AR agonists are critically dependent on the batches of albumin and collagenase used in the fat cell experiments. 20, 25 The same batch of collagenase and bovine albumin, respectively, was used throughout the biopsy study.
Genotyping
All 73 women giving self-reported data were genotyped for the Trp64Arg polymorphism of b 3 -AR. 26 Women were categorized as Arg-carriers (one homozygote and 11 heterozygotes) or Trp/Trp homozygotes (n ¼ 61).
Statistics
Values are mean þ s.d. They were normally distributed and compared using single or multiple regression, analysis of co-variance and Student's paired t-test.
We did not choose to use a fixed follow-up time because methods to study b3-AR function in human fat cells were not available until 1993, 21 although the existence of the receptor was predicted as early as 1984. 27 We considered it to be essential to include this receptor in the analysis as soon as possible. On the other hand, we could not prolong the study after 1999 because the ingredients for the lipolysis bioassay were calculated to be all consumed by then. We anticipated a linear relationship between weight changes over time and the duration of re-examination making yearly weight changes as a reliable measure. Furthermore, we considered 5 years as the shortest observation time allowed for a valid measure of longitudinal long-term changes in weight. Before starting the follow-up a power calculation was performed as follows. The major comparison was between pD2 at baseline and BMI changes (delta BMI per year). We had no a priori hypothesis as regards which particular adrenoceptor was related to BMI changes of the b-AR and a2-AR receptor We estimated a drop out frequency of 15% meaning that we had to include 85 subjects in the study to yield a statistically significant results in a two-tailed test with a power of 80% a calculated a final sample size of 73 is needed.
Results
Mean data for the 73 study subjects are shown in Table 1 . The ability of each b-AR agonist to maximally stimulate lipolysis was marked, about eightfold for dobutamine and terbutaline and about fourfold for CGP 12177. This difference in lipolytic response to CGP 1277 versus dobutamine or terbutaline is well-documented. [19] [20] [21] [22] As regards clonidine The range of change in BMI per year was also normally distributed.
The reported change in weight correlated with observation time among the weight losers (r ¼ 0.51, P ¼ 0.008) and the weight gainers (r ¼ 0.48, P ¼ 0.006). Therefore, expression of weight change per year was considered as a valid measure.
The yearly self-reported increase in BMI was compared with pD2 values at baseline (Figure 1) . No relationship to BMI changes was found with clonidine, dobutamine or terbutaline. CGP 12177, on the other hand, showed a strong negative correlation with BMI changes (r ¼
We also compared lipolytic capacity at baseline (measured either as responsiveness or as responsiveness/basal lipolysis) with self-reported changes in BMI over time. No significant relationship was observed for any of the b-AR agonists or for the a 2 -AR agonist (values not shown).
The results above were based on self-reported changes in body weight. It was possible to re-examine 4 50% of the women at our laboratory a short time after their self report. There was an excellent correlation (r ¼ 0.97) between reported and measured body weight; slope and intercept were not significantly different from one to zero, respectively. The difference between reported and measured weight in the whole group was 2.3 ± 1.7% and was not different between weigh gainers and weight losers or between those with high or low BMI. Reported body weight in the group that was not re-examined did not differ significantly as compared with those women that were also examined at our laboratory. Measured height was identical at baseline and reexamination (167 ± 8 cm).
We investigated the relationship between BMI changes and baseline adrenoceptor function in those 38 women who were re-examined at the laboratory (Figure 2 ). The findings in this subgroup were essentially the same as in the whole group of 73 women where proxy weight changes were used (Figure 1 ).
Discussion
The endogenous factors that regulate changes in body weight over time among adults are not defined. This study points at an important role of the b 3 -AR. The investigated 
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women who were healthy, non-obese at baseline had increased their average BMI with 0.7 kg/m 2 about 10 years later.
However, the longitudinal changes varied much because some lost weight and others were weight stabile. The yearly increase in mean BMI corresponds with representative data for the whole Swedish female population examined during the same period as our study. 28 Changes in BMI values among our women were obtained from self report of body weight. However, findings with laboratory measures of body weight among 450% of the investigated women ruled out b3-receptors and body weight D Andersson et al important bias in self-reported weight and results with proxy weight and exact weight yielded the same findings as regards the relationship between adrenoceptor function and weight changes. We do not believe that women possibly under reporting their weight were less willing to come for body weight measurement as reported weight did not differ between those who were examined at our laboratory and those only reporting their weight. These findings were true irrespective of use of denominator for weight changes (BMI shown in the figures, weight in kg, or percentage changes of baseline body weight).
A lipolysis bioassay was used to measure adrenoceptor function. We have earlier evaluated this assay. 29 The coefficients of variation within as well as between assay are acceptable. Furthermore, using this assay we showed that lipolytic function of adrenoceptors is stabile over time. 29 As mentioned, genetic data suggest that all b-AR subtypes influence long-term changes in body weight. In our study, there was no evidence for a role of b 1 -AR or b 2 -AR. It should be noted, though, that we only examined adipose tissue. b 1 -AR and b 2 -AR have major roles for energy homeostasis in other organs as well and they also participate in sympathetic nervous transmission. b 3 -AR, on the other hand, above all regulate energy metabolism in adipose tissue. 15 Furthermore, b 2 -AR function in fat cells could also not predict changes in body weight. b 3 -AR is a strong predictor of long-term changes in body weight. As much as 19% of longitudinal changes in BMI can be explained by baseline b 3 -AR status. This relationship is independent of age, initial BMI and duration of observation. It is less likely that other factors possibly altering body weight such as slimming attempts, menopause, pregnancy and changes in lifestyle would affect our results. However, as we categorized such events as dichotomous variables in our statistical evaluation one must interpret the results with some caution as these variables might reflect events that could work in either direction on BMI.
Furthermore, the well-known Trp64Arg polymorphism that has strong effect on the lipolytic function of b 3 -AR in human fat cells 26 also did not influence the findings with
How might b 3 -AR regulate body weight among the adult subjects? One mechanism could be that the receptor promotes lipid mobilization from white fat cells. The CGP 12177 compound used to study b 3 -AR-induced lipolysis in vitro has also direct effects on lipolysis in human subcutaneous adipose tissue in situ although it is less effective than dobutamine or terbutaline. 30 An effect on thermogenesis in brown fat cells is also plausible if we accept that these findings with white fat cells can be extrapolated to brown ones. In adults, brown adipocytes exist in adipose deposits which are generally classified as white as discussed 15 and b 3 -AR expression is paralleled with brown fat cells in these depots. 31 Furthermore, treatment of humans with a highly selective b 3 -AR agonist stimulates in vivo fat oxidation. 32 Finally, under debate are the possibilities that white fat cells may transdifferentiate to brown ones and that some white adipocytes have high-oxidative capacity. 15 We found no significant correlation between b 3 -AR sensitivity and anthropometric measures (BMI, waist to hip ratio) at baseline. Mean age was 39 years at the beginning of our investigation and one might expect a correlation as those women with low b 3 -AR sensitivity have had almost four decades to accumulate weight. However, Koda et al. 12 also report effects related to the b 3 -AR as they describe an association between cholecystokinin 1 receptor and b 3 -AR polymorphisms and midlife weight gain (between 18 and about 40 years). Accelerated weight gain often occurs in adults reaching the middle age as shown in NHANES-III, where BMI tended to increase starting from ages 20 to 29 years until ages 50-59 years. 33 The reason for this is not clear.
We can only speculate on the cause of the late onset of weight gain suggested by the lack of association between basal BMI and b 3 -AR sensitivity observed in our study. Regulation of body weight is probably different in children/ adolescence as compared with adults. Spalding et al. 34 describe differences in fat cell turnover rates between children and adults that might influence weight gain in different ways in children and adults. There are numerous other possible reasons that low b 3 -AR sensitivity associates only with midlife weight gain in women such as the need of coexisting factors including environmental factors or genetic factors. However, we do not conclude that b 3 -AR sensitivity is the major contributor to the changes in weight over time but a player in the complex multifactorial development of obesity.
Conflicting results concerning human fat cell b 3 -AR function have earlier been reported. Some studies report poor or no effect of b 3 -AR stimulation on lipolysis in human subcutaneous fat cells [35] [36] [37] and some report positive effects. 19, 22, 30, 38 The reason for these divergent results have earlier been discussed extensively 19, 38 and possible explanations might be different methodological aspects, such as choice of agonist, the sensitivity of the lipolysis assay, selection of subjects or number of investigated subjects (ranging only from 4 to 24 individuals). [35] [36] [37] However, the evidence of a functional b 3 -AR in man has also been shown both in vitro 19, 22, 38 and in vivo 30 and CGP 12177-induced lipolysis is resistant to blockade by various b 1 -AR and b 2 -AR antagonists. 19, 22 Furthermore, densities of the different b-AR subtypes from membrane preparations of subcutaneous adipocytes was studied by a radioligand binding assay by McConnaughey et al. 39 and they report no apparent difference between receptor subtype densities in the subcutaneous depot giving further support for the importance of the b 3 -AR in humans. CGP 12177 is not an endogenous agent, which of course might be considered a limitation when it comes to understanding the importance of b 3 -AR function in vivo. Another approach would be to study the effect of endogenous catecholamines in the presence of selective b 1 -AR and b 2 -AR blockers. We have not performed these experiments. These experiments would be rather tissue consuming, as we would have to study many different antagonist concentrations for the pA 2 calculations and not more than 1 g of adipose tissue could be obtained from lean subjects. Studying the effect unselective agonists with added antagonists could also be criticized as one might then object on the specificity of the blockers as well.
We report an association only between pD 2 for CGP 12177 and long-term changes in body weight, whereas responsiveness lacked significant correlation to weight change. Glycerol responsiveness (that is, maximal stimulation of lipolysis) is above all regulated by intracellullar post-receptor events, whereas agonist sensitivity (pD 2 ) illustrates receptor function. We cannot explain this difference but pD2 and responsiveness reflect totally different signaling events in the lipolytic signaling cascade.
As this study was conducted in women we do not know how relevant our findings are for body weight regulation among adult men. There are gender differences in the control of energy homeostasis as reviewed. 40 In summary, this study shows that intrinsic factors are important for long-term changes in body weight, at least among women. Subjects with low b 3 -AR function tend to increase their body weight over time whereas the opposite is true for those with a high-receptor function. This puts energy metabolism in adipose tissue in the front line among endogenous factors that control body weight in adult life. Our observations were made on women who initially were non-obese. Further studies may show whether b-AR interacts or not with physical activity and energy intake leading to excessive weight gain in subjects prone to develop obesity.
